mometasone furoate nasal spray / Generic mfg. - LARVOL DELTA

Efficacy and Safety of TQC2731 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial (ERS 2026) - P2 | "Eighty eligible patients were randomized 3:3:2 to receive subcutaneously TQC2731 420mg, 210mg, or placebo every 4 weeks, under the background therapy of mometasone furoate nasal spray (MFNS) for 24 weeks. TQC2731 exhibited excellent efficacy and safety in moderate-to-severe CRSwNP and can be regarded as an effective additional treatment option."

Clinical • P2 data • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • TSLP

Effectiveness of the Prospective Prescription Review System in Reducing Irrational Prescriptions at a Tertiary Specialty Hospital: Retrospective Cohort Study. (PubMed, JMIR Form Res) - "Pharmacist-led rule revision for mometasone furoate nasal spray led to a 1000-fold increase in identified irrational prescriptions (from 2-4 per month to 3022 in May)...Paired-organ dose standardization emerged as an important consideration in ophthalmology and otolaryngology practice. Collaboration between the prospective prescription review system and pharmacists is essential for optimizing prescription review outcomes."

Journal • Retrospective data • Oncology • Ophthalmology • Otorhinolaryngology

Sleep apnea-hypopnea in children: Evidence that Lize Tongqi decoction with acupuncture, moxibustion, and Xinwu acupoint stimulation is superior to standard Western treatment using montelucast/mometasone furoate. (PubMed, Int J Clin Pharmacol Ther) - "The combination of modified Lize Tongqi decoction with acupuncture, moxibustion, and Xinwu acupoint stimulation effectively reduced symptoms of airway obstruction and improved quality of life in pediatric patients with snoring. The combination therapy is a new, non-surgical therapeutic option for the clinical management of this potentially serious disorder."

Journal • Obstructive Sleep Apnea • Pediatrics • Respiratory Diseases • Sleep Apnea • Sleep Disorder

A combined approach for full API particle size distribution characterization in nasal spray suspensions based on their dissolution behavior. (PubMed, J Pharm Sci) - "A dissolution-based modeling strategy was established to characterize the entire PSD of starting API in mometasone furoate nasal sprays using dissolution data of finished formulations, whereas MDRS measures API PSD in the final products...Cross-validation for the model using five test batches yielded prediction errors mostly <10%, indicating acceptable performance. For nasal suspension products that typically present complex PSD features, the present method may provide a feasible auxiliary tool for guiding formulation screening and optimizing manufacturing parameters in the preliminary development stage."

Journal

Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Zhongshan People's Hospital, Guangdong, China

New trial • Allergic Rhinitis • Immunology • Inflammation

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (clinicaltrials.gov) - P2 | N=66 | Completed | Sponsor: Sanofi | Active, not recruiting ➔ Completed

Trial completion • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

A retrospective study on the effectiveness and safety of the combination of intranasal corticosteroid and intranasal antihistamine in the management of patients with allergic rhinitis. (PubMed, Front Allergy) - "There was no hospitalization, serious AEs, or treatment discontinuation due to AEs among patients. The study concluded that intranasal MF-Az spray significantly alleviated nasal and non-nasal symptoms and was well tolerated."

Journal • Retrospective data • Allergic Rhinitis • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Trial completion date: May 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

AdeCroS: Adelmidrol in Chronic Sinusitis (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: University of Campania Luigi Vanvitelli

New trial • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

CEREN2: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (clinicaltrials.gov) - P3 | N=216 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

A clinical and mechanistic study on traditional Chinese medicine herbs used in olfactory training. (PubMed, Chin Med) - "TCM-OT is a promising multi-target approach for OD. The broad activation of all OR families by herb odorants - contrasting with the limited engagement of conventional chemical odorants - provides a molecular rationale for the efficacy of TCM-OT and guidance for the selection of olfactory agents used in OT."

Journal

The Efficacy Of Rhinophototherapy Compared To Intranasal Corticosteroids On The Nasal Mucosa (clinicaltrials.gov) - P=N/A | N=35 | Completed | Sponsor: National University of Malaysia | Recruiting ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (clinicaltrials.gov) - P2 | N=64 | Enrolling by invitation | Sponsor: Sanofi | Recruiting ➔ Enrolling by invitation

Enrollment status • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

CEREN1: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (clinicaltrials.gov) - P3 | N=231 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (clinicaltrials.gov) - P2 | N=33 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | Active, not recruiting ➔ Recruiting | N=33 ➔ 64

Enrollment change • Enrollment closed • Enrollment open • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Sanofi | N=26 ➔ 64

Enrollment change • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (clinicaltrials.gov) - P2 | N=66 | Active, not recruiting | Sponsor: Sanofi | Trial completion date: Feb 2027 ➔ Aug 2026 | Trial primary completion date: Aug 2026 ➔ Mar 2026

Trial completion date • Trial primary completion date • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Comparison of Antihistamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in Allergic Rhinitis (clinicaltrials.gov) - P4 | N=32 | Not yet recruiting | Sponsor: Liaquat National Hospital & Medical College

New P4 trial • Allergic Rhinitis • Immunology • Inflammation

Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials. (PubMed, Braz J Otorhinolaryngol) - P2, P3 | "This pooled analysis demonstrated the superiority of Olo/Mom compared to its monotherapy constituents or placebo in reducing SAR symptoms over 14-days. Moreover, this study showed that Olo/Mom has a rapid onset of action and significantly improves RQLQ scores compared to placebo. Administration of Olo/Mom BID is an effective and well-tolerated option for the treatment of SAR in patients aged 12-years or older."

Journal • Retrospective data • Allergic Rhinitis • Immunology • Inflammation

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (clinicaltrials.gov) - P2 | N=64 | Recruiting | Sponsor: Sanofi

Trial initiation date • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) – The BiRCh Study (AAAAI 2026) - P2 | "Patients underwent a screening period of up to 5 weeks to determine eligibility, during which all patients were treated with daily mometasone furoate nasal spray (MFNS). Results Primary, key secondary, and safety results will be reported. Conclusions Brensocatib is being evaluated as a potential new therapy for CRSsNP, a neutrophil-mediated disease."

Clinical • P2b data • Asthma • Bronchiectasis • Genetic Disorders • Immunology • Inflammation • Nasal Polyps • Non‐Cystic Fibrosis Bronchiectasis • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Concurrent Improvement in Nasal Polyp Score and Forced Expiratory Volume in One Second with Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma: Results from the EVEREST Study (AAAAI 2026) - P4 | "Methods EVEREST (NCT04998604) randomized adults with severe CRSwNP and coexisting asthma to dupilumab 300 mg every 2 weeks (W) or omalizumab 75‒600 mg every 2W or 4W for 24W on background mometasone furoate nasal spray. More patients achieved concurrent improvement of MCID in NPS and ≥100 ml increase in FEV1 with dupilumab vs omalizumab at W4 (34.3% vs 11.2%), W12 (42.5% vs 16.2%), and W24 (46.4% vs 21.8%). Conclusions A higher number of patients with severe CRSwNP and coexisting asthma achieved concurrent improvements in objective disease measures in CRSwNP (NPS) and asthma (FEV1) with dupilumab than omalizumab."

Clinical • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Quaternized chitosan-coated liposomes enable pH-independent nasal mucoadhesion and a sustained local depot for mometasone furoate. (PubMed, Eur J Pharm Biopharm) - "In a rat model of allergic rhinitis, QCS-MF-Lip significantly alleviated symptoms and demonstrated superior therapeutic efficacy relative to Nasonex®, as reflected by reduced histamine levels and enhanced anti-inflammatory effects. These results suggest that permanently cationic QCS is a promising strategy for pH-independent nasal mucoadhesion and the establishment of a local intranasal drug depot."

Journal • Allergic Rhinitis • Immunology • Inflammation

A prospective, randomized, controlled study comparing the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in the treatment of moderate to severe allergic rhinitis symptoms (ChiCTR) - P4 | N=200 | Not yet recruiting | Sponsor: China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University

New P4 trial • Allergic Rhinitis • Immunology • Inflammation

Integrating In Vitro Performance and In Vivo Patient-Reported Outcomes of a Mometasone Furoate Nasal Spray Device: A Translational Evaluation. (PubMed, J Aerosol Med Pulm Drug Deliv) - "The liquid VP3 nasal spray device delivering mometasone furoate demonstrated reliable in vitro performance and favorable patient acceptability in UACS. The correspondence between deposition behavior and patient-reported tolerability supports its suitability for INCS delivery and warrants further evaluation in larger, longer-term studies."

Journal • Preclinical • Allergic Rhinitis • Chronic Cough • Cough • Immunology • Inflammation • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis